Guselkumab improves joint pain in patients with pustulotic arthro-osteitis: A retrospective pilot study.

Abstract

Pustulotic arthro-osteitis (PAO) is an osteoarticular complication of palmoplantar pustulosis (PPP). Although guselkumab, an anti-interleukin-23p19 antibody, has been shown to be effective for PPP, its efficacy for PAO is still not well understood. We conducted a retrospective observational study to evaluate the effectiveness of 28-week guselkumab treatment for five PAO patients in daily clinical practice. Four patients had sternoclavicular arthritis, and one had only sacroiliitis. Guselkumab improved pain visual assessment scale scores in all five patients by 54.2% (11.1-87.5%) on average at week 28 compared with baseline, and discontinuation or dose reduction of analgesics was possible in four of them. Three patients showed clinically significant improvement in Bath Ankylosing Spondylitis Disease Activity Index of 2 or more. On the other hand, beneficial change in Ankylosing Spondylitis Disease Activity Score of 1.1 or more was observed in only one patient. Bone scintigraphy demonstrated decreased uptake in sternoclavicular joints after guselkumab treatment in all four patients with sternoclavicular arthritis. Improvement of Palmoplantar Pustulosis Area and Severity Index was also confirmed. Guselkumab can be a treatment option for intractable PAO.

• Authors: Natsumi Ikumi, Hideki Fujita, Tadashi Terui
• Journal: The Journal of dermatology (J Dermatol) Vol. 48 Issue 2 Pg. 199-202 (Feb 2021) ISSN: 1346-8138 [Electronic] England
• PMID: 33051886 (Publication Type: Journal Article, Observational Study)
• Copyright: © 2020 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.

Chemical References

• Antibodies, Monoclonal, Humanized
• guselkumab

Topics

• Antibodies, Monoclonal, Humanized
• Arthralgia
• Humans
• Osteitis (diagnostic imaging, drug therapy)
• Pilot Projects
• Psoriasis
• Retrospective Studies